Table 1.

Description of Studies(N=92)

Characteristic	n (%) or Median [25th–75th percentile]
Location
Adult CRC	19 (21%)
Pediatric CRC	73 (79%)
Trial type
Phase I–II	29 (32%)
Phase III	23 (25%)
IND/IDE	55 (60%)
Multi-center	64 (70%)
Rare/orphan disease	18 (20%)
Investigator initiated	54 (59%)
Funding
NIH	30 (33%)
Industry	42 (46%)
Investigator experience
<6 previous studies	25 (27%)
>10 previous studies	55 (60%)
Study Coordinator experience
5 or fewer years	16 (17%)
>10 years	41 (45%)
Currently open for study activities	51 (55%)
Local target for enrollment	11[5 – 40]
Days between study open and first patient enrolled	68 [22 – 186]